By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Ironwood Pharmaceuticals 

301 Binney Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-621-7722 Fax: 617-494-0480


SEARCH JOBS

Ironwood Pharmaceuticals (NASDAQ: IRWD) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our team to passionately pursue excellence. We discovered, developed and are commercializing linaclotide, which is approved in the United States and a number of other countries. Our pipeline priorities include exploring further opportunities for linaclotide, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to address patient needs across the upper and lower gastrointestinal tract. Ironwood was founded in 1998 and is headquartered in Cambridge, Mass. Connect with us at www.ironwoodpharma.com or on Twitter at www.twitter.com/ironwoodpharma.


Key Statistics


Email:
Ownership: Public

Web Site: Ironwood Pharmaceuticals
Employees:
Symbol: IRWD
 



Industry
Pharmaceutical






Company News
Ironwood Pharmaceuticals (IRWD) Appoints Lawrence Olanoff, M.D., Ph.D., To Board Of Directors 4/16/2015 12:58:00 PM
Ironwood Pharmaceuticals (IRWD) To Host First Quarter 2015 Investor Update Call 4/16/2015 12:27:24 PM
Ironwood Pharmaceuticals (IRWD) Release: Updated Direct-to-Consumer Awareness Campaign Available For LINZESS (linaclotide) 3/31/2015 3:00:34 PM
EXACT Sciences Corporation (EXAS) And Ironwood Pharmaceuticals (IRWD) Enter Co-Promotion Agreement For Cologuard 3/9/2015 9:57:27 AM
Ironwood Pharmaceuticals (IRWD) To Present At Barclays Global Healthcare Conference 3/5/2015 11:03:56 AM
Ironwood Pharmaceuticals (IRWD) Initiates Phase I Clinical Study Of sGC Stimulator IW-1973 3/5/2015 10:03:20 AM
Ironwood Pharmaceuticals (IRWD) To Present At Cowen and Company 35th Annual Health Care Conference 2/24/2015 12:08:59 PM
Ironwood Pharmaceuticals (IRWD) Provides Fourth Quarter 2014 Investor Update 2/13/2015 10:03:27 AM
Ironwood Pharmaceuticals (IRWD) Reports Positive Top-Line Data From Exploratory Phase IIa Trial Of IW-3718 In Refractory Gastroesophageal Reflux Disease 2/4/2015 10:59:16 AM
Ironwood Pharmaceuticals (IRWD) To Host Fourth Quarter 2014 Investor Update Call 1/30/2015 10:49:51 AM
12345678910...
//-->